Pfizer posts Q1FY22 PAT of Rs. 199.91 Cr
The company posted net profit of Rs.124.45 crores for the period ended June 30, 2020.
The company posted net profit of Rs.124.45 crores for the period ended June 30, 2020.
The company posted net profit f Rs.85.45 crores for the period ended June 30, 2020.
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
The company reported total income Rs.18.57 crores during the period ended June 30, 2020.
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
The company had announced the expected date of completion of sale and disposal of the said undertaking is 90 days from the date of signing the Definitive Agreements.
Subscribe To Our Newsletter & Stay Updated